A proof of concept for structure-based vaccine design targeting RSV in humans

RESPIRATORY SYNCYTIAL VIRUS DISEASE IN INFANTS DESPITE PRIOR ADMINISTRATION OF ANTIGENIC INACTIVATED VACCINE12

KIM, H. W., CANCHOLA, J. G., BRANDT, C. D., PYLES, G., CHANOCK, R. M., JENSEN, K., & PARROTT, R. H. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120955 · Cited by 1,981 · see citing works

Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus

McLellan, J. S., Chen, M., Joyce, M. G., Sastry, M., Stewart-Jones, G. B. E., Yang, Y., Zhang, B., Chen, L., Srivatsan, S., Zheng, A., et al. (2013) · Science · doi:10.1126/science.1243283 · Cited by 1,126 · see citing works

AN EPIDEMIOLOGIC STUDY OF ALTERED CLINICAL REACTIVITY TO RESPIRATORY SYNCYTIAL (RS) VIRUS INFECTION IN CHILDREN PREVIOUSLY VACCINATED WITH AN INACTIVATED RS VIRUS VACCINE

Kapikian, A. Z., MITCHELL, R. H., Chanock, R. M., Shvedoff, R. A., & STEWART, C. E. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120954 · Cited by 1,035 · see citing works

Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody

McLellan, J. S., Chen, M., Leung, S., Graepel, K. W., Du, X., Yang, Y., Zhou, T., Baxa, U., Yasuda, E., Beaumont, T., et al. (2013) · Science · doi:10.1126/science.1234914 · Cited by 883 · see citing works

Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level

Glezen, W. P., Paredes, A., Allison, J. E., Taber, L. H., & Frank, A. L. (1981) · The Journal of Pediatrics · doi:10.1016/s0022-3476(81)80829-3 · Cited by 684 · see citing works

FIELD EVALUATION OF A RESPIRATORY SYNCYTIAL VIRUS VACCINE AND A TRIVALENT PARAINFLUENZA VIRUS VACCINE IN A PEDIATRIC POPULATION1

CHIN, J., Magoffin, R. L., Shearer, L. A., SCHIEBLE, J. H., & Lennette, E. H. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120957 · Cited by 630 · see citing works

RESPIRATORY VIRUS IMMUNIZATION

Fulginiti, V. A., Eller, J. J., Sieber, O. F., Joyner, J. W., Minamitani, M., & Meiklejohn, G. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120956 · Cited by 609 · see citing works

The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates

Mazur, N. I., Higgins, D., Nunes, M. C., Melero, J. A., Langedijk, A. C., Horsley, N., Buchholz, U. J., Openshaw, P., McLellan, J. S., Englund, J. A., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30292-5 · Cited by 457 · see citing works

Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes

McLellan, J. S., Yang, Y., Graham, B. S., & Kwong, P. D. (2011) · Journal of Virology · doi:10.1128/jvi.00555-11 · Cited by 433 · see citing works

Prefusion F–specific antibodies determine the magnitude of RSV neutralizing activity in human sera

Ngwuta, J. O., Chen, M., Modjarrad, K., Joyce, M. G., Kanekiyo, M., Kumar, A., Yassine, H. M., Moin, S. M., Killikelly, A. M., Chuang, G., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac4241 · Cited by 433 · see citing works

Mutants of Pertussis Toxin Suitable for Vaccine Development

Pizza, M., Covacci, A., Bartoloni, A., Perugini, M., Nencioni, L., Magistris, M. T. D., Villa, L., Nucci, D., Manetti, R., Bugnoli, M., et al. (1989) · Science · doi:10.1126/science.2683073 · Cited by 311 · see citing works

Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine

Murphy, B. R., Prince, G. A., Walsh, E. E., Kim, H. W., Parrott, R. H., Hemming, V. G., Rodriguez, W. J., & Chanock, R. M. (1986) · Journal of Clinical Microbiology · doi:10.1128/jcm.24.2.197-202.1986 · Cited by 304 · see citing works

Impaired Antibody-Mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus

Habibi, M. S., Jóźwik, A., Makris, S., Dunning, J. W., Paras, A., DeVincenzo, J. P., de Haan, C. A. M., Wrammert, J., Openshaw, P., & Chiu, C. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201412-2256oc · Cited by 289 · see citing works

Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers

Swanson, K. A., Settembre, E. C., Shaw, C. A., Dey, A. K., Rappuoli, R., Mandl, C. W., Dormitzer, P. R., & Carfi, A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106536108 · Cited by 285 · see citing works

Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention

Magro, M., Mas, V., Chappell, K., Vázquez, M., Cano, O., Luque, D., Terrón, M. C., Melero, J. A., & Palomo, C. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1115941109 · Cited by 271 · see citing works

Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors

Gilman, M. S. A., Castellanos, C. A., Chen, M., Ngwuta, J. O., Goodwin, E. C., Moin, S. M., Más, V., Melero, J. A., Wright, P. F., Graham, B. S., et al. (2016) · Science Immunology · doi:10.1126/sciimmunol.aaj1879 · Cited by 239 · see citing works

Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity

Murphy, B. R., & Walsh, E. E. (1988) · Journal of Clinical Microbiology · doi:10.1128/jcm.26.8.1595-1597.1988 · Cited by 228 · see citing works

Relationship of Serum Antibody to Risk of Respiratory Syncytial Virus Infection in Elderly Adults

Falsey, A. R., & Walsh, E. E. (1998) · The Journal of Infectious Diseases · doi:10.1086/517376 · Cited by 173 · see citing works

Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV

Joyce, M. G., Zhang, B., Ou, L., Chen, M., Chuang, G., Druz, A., Kong, W., Lai, Y., Rundlet, E. J., Tsybovsky, Y., et al. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3267 · Cited by 168 · see citing works

Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein

Gilman, M. S. A., Moin, S. M., Más, V., Chen, M., Patel, N., Kari, K., Zhu, Q., Kabeche, S. C., Kumar, A., Palomo, C., et al. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1005035 · Cited by 152 · see citing works

Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation

Goodwin, E. C., Gilman, M., Wrapp, D., Chen, M., Ngwuta, J. O., Moin, S., Bai, P., Sivasubramanian, A., Connor, R., Wright, P., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.01.005 · Cited by 146 · see citing works

Antigenic Structure of Human Respiratory Syncytial Virus Fusion Glycoprotein

López, J. A., Bustos, R., Örvell, C., Berois, M., Arbiza, J., García‐Barreno, B., & Melero, J. A. (1998) · Journal of Virology · doi:10.1128/jvi.72.8.6922-6928.1998 · Cited by 123 · see citing works

A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein

Mousa, J. J., Kose, N., Matta, P., Gilchuk, P., & Crowe, J. E. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.271 · Cited by 111 · see citing works

A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age

August, A., Glenn, G. M., Kpamegan, E. P., Hickman, S. P., Jani, D., Lu, H., Thomas, D. N., Wen, J., Piedra, P. A., & Fries, L. F. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.05.045 · Cited by 98 · see citing works

Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus

Wen, X., Mousa, J. J., Bates, J. T., Lamb, R. A., Crowe, J. E., & Jardetzky, T. S. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.272 · Cited by 94 · see citing works

Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state

Rossey, I., Gilman, M. S. A., Kabeche, S. C., Sedeyn, K., Wrapp, D., Kanekiyo, M., Chen, M., Más, V., Spitaels, J., Melero, J. A., et al. (2017) · Nature Communications · doi:10.1038/ncomms14158 · Cited by 84 · see citing works

Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults

Fries, L. F., Shinde, V., Stoddard, J. J., Thomas, D. N., Kpamegan, E. P., Lu, H., Smith, G., Hickman, S. P., Piedra, P. A., & Glenn, G. M. (2017) · Immunity & Ageing · doi:10.1186/s12979-017-0090-7 · Cited by 75 · see citing works

Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein

Tian, D., Battles, M. B., Moin, S. M., Chen, M., Modjarrad, K., Kumar, A., Kanekiyo, M., Graepel, K. W., Taher, N. M., Hotard, A. L., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01858-w · Cited by 71 · see citing works

Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines

Simões, E. A. F., Tan, D. H. S., Ohlsson, A., Sales, V., & Wang, E. E. L. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00388-7 · Cited by 53 · see citing works

Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein

Mousa, J. J., Sauer, M. F., Sevy, A. M., Finn, J. A., Bates, J. T., Alvarado, G. S., King, H. G., Loerinc, L. B., Fong, R. H., Doranz, B. J., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609449113 · Cited by 53 · see citing works

Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater In Vivo Protection than the Murine Precursor of Palivizumab

Zhao, M., Zheng, Z., Chen, M., Modjarrad, K., Zhang, W., Zhan, L.-T., Cao, J., Sun, Y., McLellan, J. S., Graham, B. S., et al. (2017) · Journal of Virology · doi:10.1128/jvi.00176-17 · Cited by 35 · see citing works

Epitope-Specific Serological Assays for RSV: Conformation Matters

Phung, E., Chang, L. A., Morabito, K. M., Kanekiyo, M., Chen, M., Nair, D., Kumar, A., Chen, G. L., Ledgerwood, J. E., Graham, B. S., et al. (2019) · Vaccines · doi:10.3390/vaccines7010023 · Cited by 34 · see citing works

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · see citing works

SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness

Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615 · see citing works

A guide to vaccinology: from basic principles to new developments

Pollard, A. J., & Bijker, E. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00479-7 · Cited by 1,593 · see citing works

mRNA vaccines for infectious diseases: principles, delivery and clinical translation

Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555 · see citing works

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Hsieh, C.-L., Goldsmith, J. A., Schaub, J. M., DiVenere, A. M., Kuo, H.-C., Javanmardi, K., Le, K. C., Wrapp, D., Lee, A. G., Liu, Y., et al. (2020) · Science · doi:10.1126/science.abd0826 · Cited by 1,303 · see citing works

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Corbett, K. S., Flynn, B., Foulds, K. E., Francica, J. R., Boyoglu-Barnum, S., Werner, A. P., Flach, B., O’Connell, S., Bock, K. W., Minai, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024671 · Cited by 1,066 · see citing works

SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates

Kyriakidis, N. C., López‐Cortés, A., Vásconez-González, J., Barreto-Grimaldos, A., & Ortiz‐Prado, E. (2021) · npj Vaccines · doi:10.1038/s41541-021-00292-w · Cited by 682 · see citing works

Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults

Wilson, E. M. P., Goswami, J., Baqui, A. H., Doreski, P. A., Marc, G. P., Zaman, K., Monroy, J., Duncan, C. J. A., Ujiie, M., Rämet, M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307079 · Cited by 517 · see citing works

The role of vaccines in combatting antimicrobial resistance

Micoli, F., Bagnoli, F., Rappuoli, R., & Serruto, D. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00506-3 · Cited by 504 · see citing works

Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape

Mazur, N. I., Terstappen, J., Baral, R., Bardají, A., Beutels, P., Buchholz, U. J., Cohen, C., Crowe, J. E., Cutland, C., Eckert, L. O., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00291-2 · Cited by 428 · see citing works

Leveraging artificial intelligence in the fight against infectious diseases

Wong, F. J., de la Fuente‐Núñez, C., & Collins, J. J. (2023) · Science · doi:10.1126/science.adh1114 · Cited by 320 · see citing works

Next‐Generation Vaccines: Nanoparticle‐Mediated DNA and mRNA Delivery

Ho, W., Gao, M., Li, F., Li, Z., Zhang, X., & Xu, X. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202001812 · Cited by 261 · see citing works

Accelerated COVID-19 vaccine development: milestones, lessons, and prospects

Bok, K., Sitar, S., Graham, B. S., & Mascola, J. R. (2021) · Immunity · doi:10.1016/j.immuni.2021.07.017 · Cited by 254 · see citing works

Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy

Du, S., Cao, Y., Zhu, Q., Yü, P., Qi, F., Wang, G., Du, X., Bao, L., Deng, W., Zhu, H., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.035 · Cited by 238 · see citing works

mRNA vaccines for infectious diseases — advances, challenges and opportunities

Pardi, N., & Krammer, F. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01042-y · Cited by 246 · see citing works

De novo protein design enables the precise induction of RSV-neutralizing antibodies

Sesterhenn, F., Yang, C., Bonet, J., Cramer, J. T., Wen, X., Wang, Y., Chiang, C.-I., Abriata, L. A., Kucharska, I., Castoro, G., et al. (2020) · Science · doi:10.1126/science.aay5051 · Cited by 191 · see citing works

Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection

Espeseth, A. S., Cejas, P. J., Citron, M. P., Wang, D., DiStefano, D. J., Callahan, C., Donnell, G. O., Galli, J. D., Swoyer, R., Touch, S., et al. (2020) · npj Vaccines · doi:10.1038/s41541-020-0163-z · Cited by 190 · see citing works

Immunological Lessons from Respiratory Syncytial Virus Vaccine Development

Ruckwardt, T. J., Morabito, K. M., & Graham, B. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.08.007 · Cited by 185 · see citing works

Neutrophilic inflammation in the respiratory mucosa predisposes to RSV infection

Habibi, M. S., Thwaites, R. S., Chang, M., Jóźwik, A., Paras, A., Kirsebom, F. C. M., Varese, A., Owen, A., Cuthbertson, L., James, P. L., et al. (2020) · Science · doi:10.1126/science.aba9301 · Cited by 174 · see citing works

SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity

Joyce, M. G., Chen, W., Sankhala, R. S., Hajduczki, A., Thomas, P. V., Choe, M., Martinez, E. J., Chang, W. C., Peterson, C. E., Morrison, E. B., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110143 · Cited by 179 · see citing works

Respiratory syncytial virus infection and novel interventions

Langedijk, A. C., & Bont, L. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00919-w · Cited by 178 · see citing works

Novel vaccine technologies for the 21st century

Mascola, J. R., & Fauci, A. S. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0243-3 · Cited by 171 · see citing works

A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults

Aliprantis, A. O., Shaw, C. A., Griffin, P., Farinola, N., Railkar, R. A., Cao, X., Liu, W., Sachs, J. R., Swenson, C. J., Lee, H., et al. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1829899 · Cited by 149 · see citing works

Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study

Schmöele-Thoma, B., Zareba, A., Jiang, Q. L., Maddur, M. S., Danaf, R., Mann, A., Eze, K., Fok‐Seang, J., Kabir, G., Catchpole, A. P., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116154 · Cited by 138 · see citing works

Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines

Topalidou, X., Kalergis, A. M., & Papazisis, G. (2023) · Pathogens · doi:10.3390/pathogens12101259 · Cited by 127 · see citing works

A respiratory syncytial virus (RSV) F protein nanoparticle vaccine focuses antibody responses to a conserved neutralization domain

Swanson, K. A., Rainho-Tomko, J. N., Williams, Z. P., Lanza, L., Peredelchuk, M., Kishko, M., Pavot, V., Alamares-Sapuay, J. G., Adhikarla, H., Gupta, S., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aba6466 · Cited by 115 · see citing works

Prevention and Treatment Strategies for Respiratory Syncytial Virus (RSV)

Gatt, D., Martin, I., AlFouzan, R., & Moraes, T. J. (2023) · Pathogens · doi:10.3390/pathogens12020154 · Cited by 120 · see citing works

Current Challenges in Vaccinology

Kennedy, R. B., Ovsyannikova, I. G., Palese, P., & Poland, G. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01181 · Cited by 113 · see citing works

Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years

Williams, K. L., Bastian, A. R., Feldman, R., Omoruyi, E. V. E., Paepe, E. D., Hendriks, J., van Zeeburg, H., Godeaux, O., Langedijk, J. P. M., Schuitemaker, H., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa193 · Cited by 108 · see citing works

Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine

Che, Y., Gribenko, A. V., Song, X., Handke, L. D., Efferen, K. S., Tompkins, K. R., Kodali, S., Nuñez, L., Prasad, A. K., Phelan, L., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.ade6422 · Cited by 102 · see citing works

A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine

Walsh, E. E., Falsey, A. R., Scott, D. A., Gurtman, A., Zareba, A., Jansen, K. U., Gruber, W. C., Dormitzer, P. R., Swanson, K. A., Radley, D. R., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab612 · Cited by 97 · see citing works

Vaccinology in the post−COVID-19 era

Rappuoli, R., Gregorio, E. D., Giudice, G. D., Phogat, S. K., Pecetta, S., Pizza, M., & Hanon, E. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2020368118 · Cited by 96 · see citing works

Palivizumab Prophylaxis in Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection

Caserta, M. T., O’Leary, S. T., Muñoz, F. M., Ralston, S. L., O’Leary, S. T., Campbell, J. D., Ardura, M. I., Banerjee, R., Bryant, K. A., Caserta, M. T., et al. (2023) · PEDIATRICS · doi:10.1542/peds.2023-061803 · Cited by 95 · see citing works

Bottom-up de novo design of functional proteins with complex structural features

Yang, C., Sesterhenn, F., Bonet, J., van Aalen, E. A., Scheller, L., Abriata, L. A., Cramer, J. T., Wen, X., Rosset, S., Georgeon, S., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-020-00699-x · Cited by 84 · see citing works

Structure-Based Design of Nipah Virus Vaccines: A Generalizable Approach to Paramyxovirus Immunogen Development

Loomis, R. J., Stewart-Jones, G. B. E., Tsybovsky, Y., Caringal, R. T., Morabito, K. M., McLellan, J. S., Chamberlain, A. L., Nugent, S. T., Hutchinson, G. B., Kueltzo, L. A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00842 · Cited by 90 · see citing works

Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study

SADOFF, J. C., Paepe, E. D., DeVincenzo, J. P., Gymnopoulou, E., Menten, J., Murray, B. J., Bastian, A. R., Vandebosch, A., Haazen, W., Noulin, N., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab003 · Cited by 89 · see citing works

Structure-based design of prefusion-stabilized human metapneumovirus fusion proteins

Hsieh, C., Rush, S. A., Palomo, C., Chou, C., Pickens, W., Más, V., & McLellan, J. S. (2022) · Nature Communications · doi:10.1038/s41467-022-28931-3 · Cited by 88 · see citing works

The RH5-CyRPA-Ripr Complex as a Malaria Vaccine Target

Ragotte, R. J., Higgins, M. K., & Draper, S. J. (2020) · Trends in Parasitology · doi:10.1016/j.pt.2020.04.003 · Cited by 84 · see citing works

Multivalent antigen display on nanoparticle immunogens increases B cell clonotype diversity and neutralization breadth to pneumoviruses

Ols, S., Lenart, K., Cerveira, R. A., Miranda, M. C., Brunette, N., Kochmann, J., Corcoran, M., Skotheim, R., Philomin, A., Cagigi, A., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.08.011 · Cited by 80 · see citing works

Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine

Falsey, A. R., Walsh, E. E., Scott, D. A., Gurtman, A., Zareba, A., Jansen, K. U., Gruber, W. C., Dormitzer, P. R., Swanson, K. A., Jiang, Q. L., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab611 · Cited by 82 · see citing works

Differences Between RSV A and RSV B Subgroups and Implications for Pharmaceutical Preventive Measures

Nuttens, C., Moyersoen, J., Curcio, D., Torres, Z. A., Baay, M. F. D., Vroling, H., Gessner, B. D., & Begier, E. M. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-01012-2 · Cited by 82 · see citing works

Development of mRNA vaccines against respiratory syncytial virus (RSV)

Qiu, X., Xu, S., Lu, Y., Luo, Z., Yan, Y., Wang, C., & Ji, J. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.10.001 · Cited by 83 · see citing works

A yeast-expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates

Pino, M., Abid, T., Ribeiro, S. P., Edara, V. V., Floyd, K. A., Smith, J. C., Latif, M. B., Sánchez, G. P., Dutta, D., Wang, S., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abh3634 · Cited by 77 · see citing works

Community-Wide Experimental Evaluation of the PROSS Stability-Design Method

Peleg, Y., Vincentelli, R., Collins, B. M., Chen, K., Livingstone, E. K., Weeratunga, S. K., Leneva, N., Guo, Q., Remans, K., Perez, K., et al. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.166964 · Cited by 74 · see citing works

Therapeutic Antibodies in Medicine

Sharma, P., Joshi, R. V., Pritchard, R., Xu, K., & Eicher, M. A. (2023) · Molecules · doi:10.3390/molecules28186438 · Cited by 76 · see citing works

Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine

Loomis, R. J., DiPiazza, A. T., Falcone, S., Ruckwardt, T. J., Morabito, K. M., Abiona, O. M., Chang, L. A., Caringal, R. T., Presnyak, V., Narayanan, E., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.772864 · Cited by 70 · see citing works

The road to approved vaccines for respiratory syncytial virus

Ruckwardt, T. J. (2023) · npj Vaccines · doi:10.1038/s41541-023-00734-7 · Cited by 75 · see citing works

Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics

Durham, N. D., Agrawal, A., Waltari, E., Croote, D., Zanini, F., Davidson, E., Fouch, M. E., Smith, O., Carabajal, E., Pak, J. E., et al. (2019) · eLife · doi:10.7554/elife.52384 · Cited by 69 · see citing works

Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses

Mukhamedova, M., Wrapp, D., Shen, C., Gilman, M. S. A., Ruckwardt, T. J., Schramm, C. A., Ault, L., Chang, L. A., Derrien-Colemyn, A., Lucas, S. A. M., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.03.004 · Cited by 68 · see citing works

Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial

Ruckwardt, T. J., Morabito, K. M., Phung, E., Crank, M. C., Costner, P. J. M., Holman, L. A., Chang, L. A., Hickman, S. P., Berkowitz, N. M., Gordon, I. J., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00098-9 · Cited by 68 · see citing works

Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial

Bebia, Z., Reyes, O., Jeanfreau, R. J., Kantele, A., León, R. G. D., Sánchez, M. G., Banooni, P., Gardener, G. J., Rasero, J. L. B., Pardilla, M. B. E., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad024 · Cited by 68 · see citing works

The impact of human vaccines on bacterial antimicrobial resistance. A review

Jansen, K., Gruber, W., Simon, R., Wassil, J., & Anderson, A. S. (2021) · Environmental Chemistry Letters · doi:10.1007/s10311-021-01274-z · Cited by 64 · see citing works

SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates

Li, T., Zheng, Q., Yu, H. J., Wu, D., Xue, W., Xiong, H., Huang, X., Nie, M., Yue, M., Rong, R., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1821583 · Cited by 67 · see citing works

Role of Respiratory Syncytial Virus in Pediatric Pneumonia

Bianchini, S., Silvestri, E., Argentiero, A., Fainardi, V., Pisi, G., & Esposito, S. (2020) · Microorganisms · doi:10.3390/microorganisms8122048 · Cited by 66 · see citing works

Prototype Pathogen Approach for Vaccine and Monoclonal Antibody Development: A Critical Component of the NIAID Plan for Pandemic Preparedness

Cassetti, M. C., Pierson, T. C., Patterson, L. J., Bok, K., DeRocco, A. J., Deschamps, A. M., Graham, B. S., Erbelding, E. J., & Fauci, A. S. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac296 · Cited by 66 · see citing works

Structure and function of a malaria transmission blocking vaccine targeting Pfs230 and Pfs230-Pfs48/45 proteins

Singh, K., Burkhardt, M., Nakuchima, S., Herrera, R., Muratova, O. V., Gittis, A. G., Kelnhofer, E., Reiter, K., Smelkinson, M. G., Veltri, D., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-01123-9 · Cited by 65 · see citing works

A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike

Lu, M., Dravid, P., Zhang, Y., Trivedi, S., Li, A., Harder, O. E., Mahesh, K. C., Chaiwatpongsakorn, S., Zani, A., Kenney, A. D., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2026153118 · Cited by 65 · see citing works

Host Responses to Respiratory Syncytial Virus Infection

Agac, A., Kolbe, S. M., Ludlow, M., Osterhaus, A. D. M. E., Meineke, R., & Rimmelzwaan, G. F. (2023) · Viruses · doi:10.3390/v15101999 · Cited by 69 · see citing works

Innovations in structure-based antigen design and immune monitoring for next generation vaccines

Ward, A. B., & Wilson, I. A. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.03.013 · Cited by 62 · see citing works

Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines

Biagi, C., Dondi, A., Scarpini, S., Rocca, A., Vandini, S., Poletti, G., & Lanari, M. (2020) · Vaccines · doi:10.3390/vaccines8040672 · Cited by 61 · see citing works

Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults

Shaw, C. A., Essink, B. J., Harper, C., Mithani, R., Kapoor, A., Dhar, R., Wilson, L. A., Guo, R., Panozzo, C. A., Wilson, E. M. P., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae081 · Cited by 61 · see citing works

Vaccines’ New Era-RNA Vaccine

Zhou, W., Jiang, L., Liao, S., Wu, F., Yang, G., Hou, L., Liu, L., Pan, X., Jia, W. W.-G., & Zhang, Y. (2023) · Viruses · doi:10.3390/v15081760 · Cited by 62 · see citing works

Current progress in the development of prophylactic and therapeutic vaccines

Li, T., Qian, C., Gu, Y., Zhang, J., Li, S., & Xia, N. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2230-4 · Cited by 57 · see citing works

Promoting versatile vaccine development for emerging pandemics

Monrad, J. T., Sandbrink, J. B., & Cherian, N. G. (2021) · npj Vaccines · doi:10.1038/s41541-021-00290-y · Cited by 58 · see citing works

Clinical development of therapeutic mRNA applications

Żak, M. M., & Zangi, L. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.034 · Cited by 62 · see citing works

The Journey to RSV Vaccines — Heralding an Era of Structure-Based Design

Graham, B. S. (2023) · New England Journal of Medicine · doi:10.1056/nejmp2216358 · Cited by 54 · see citing works

Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus

Lin, G.-L., Drysdale, S. B., Snape, M. D., O’Connor, D., Brown, A., MacIntyre-Cockett, G., Mellado-Gomez, E., de Cesare, M., Bonsall, D., Ansari, M. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25265-4 · Cited by 48 · see citing works

A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccine

Chang, L. A., Phung, E., Crank, M. C., Morabito, K. M., Villafana, T. L., Dubovsky, F., Falloon, J., Esser, M. T., Lin, B. C., Chen, G. L., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.ade0424 · Cited by 45 · see citing works

Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults

Goswami, J., Baqui, A. H., Doreski, P. A., Marc, G. P., Jimenez, G., Ahmed, S., Zaman, K., Duncan, C. J. A., Ujiie, M., Rämet, M., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae316 · Cited by 47 · see citing works

Structural basis for respiratory syncytial virus and human metapneumovirus neutralization

Miller, R. J., & Mousa, J. J. (2023) · Current Opinion in Virology · doi:10.1016/j.coviro.2023.101337 · Cited by 46 · see citing works

Can We AlphaFold Our Way Out of the Next Pandemic?

Higgins, M. K. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167093 · Cited by 46 · see citing works

Innate and adaptive immune responses in respiratory virus infection: implications for the clinic

Stambas, J., Lu, C., & Tripp, R. A. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1807945 · Cited by 46 · see citing works

Antibody-guided structure-based vaccines

Kwong, P. D., DeKosky, B. J., & Ulmer, J. B. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101428 · Cited by 43 · see citing works

Profiles of current COVID-19 vaccines

Heinz, F. X., & Stiasny, K. (2021) · Wiener klinische Wochenschrift · doi:10.1007/s00508-021-01835-w · Cited by 45 · see citing works

Controlled Human Infection Models To Accelerate Vaccine Development

Choy, R. K. M., Bourgeois, A. L., Ockenhouse, C. F., Walker, R. I., Sheets, R., & Flores, J. (2022) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-21 · Cited by 44 · see citing works

Priorities for developing respiratory syncytial virus vaccines in different target populations

Drysdale, S. B., Barr, R. S., Rollier, C. S., Green, C., Pollard, A. J., & Sande, C. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax2466 · Cited by 43 · see citing works

Antibody recognition of the Pneumovirus fusion protein trimer interface

Huang, J., Diaz, D., & Mousa, J. J. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008942 · Cited by 43 · see citing works

50 Years of structural immunology

Wilson, I. A., & Stanfield, R. L. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100745 · Cited by 43 · see citing works

Using cross-species vaccination approaches to counter emerging infectious diseases

Warimwe, G. M., Francis, M. J., Bowden, T. A., Thumbi, S. M., & Charleston, B. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00567-2 · Cited by 42 · see citing works

Three Dose Levels of a Maternal Respiratory Syncytial Virus Vaccine Candidate Are Well Tolerated and Immunogenic in a Randomized Trial in Nonpregnant Women

Schwarz, T. F., Johnson, C., Grigat, C., Apter, D. L., Csonka, P., Lindblad, N., Nguyên, T. L.-A., Gao, F. F., Qian, H., Tullio, A. N., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab317 · Cited by 42 · see citing works

Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial

Houser, K. V., Gaudinski, M. R., Happe, M., Narpala, S., Verardi, R., Sarfo, E. K., Corrigan, A. R., Wu, R., Rothwell, R. S., Novik, L., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101477 · Cited by 42 · see citing works

Divergent age-related humoral correlates of protection against respiratory syncytial virus infection in older and young adults: a pilot, controlled, human infection challenge model

Ascough, S., Dayananda, P., Kalyan, M., Ung, S. K. A., Gardener, Z., Bergstrom, E., Paterson, S., Kar, S., Avadhan, V., Thwaites, R. S., et al. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(22)00103-9 · Cited by 42 · see citing works

Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV-Seropositive Children 12–24 Months

Stuart, A. S. V., Virta, M., Williams, K. L., Seppä, I., Hartvickson, R., Greenland, M., Omoruyi, E. V. E., Bastian, A. R., Haazen, W., Salisch, N. C., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac407 · Cited by 41 · see citing works

Efficacious human metapneumovirus vaccine based on AI-guided engineering of a closed prefusion trimer

Bakkers, M. J. G., Ritschel, T., Tiemessen, M. M., Dijkman, J., Zuffianò, A. A., Yu, X., van Overveld, D., Le, L., Voorzaat, R., van Haaren, M. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50659-5 · Cited by 41 · see citing works

A Safe and Effective Mucosal RSV Vaccine Consisting of RSV Phosphoprotein and Flagellin Variant

Zhao, B., Yang, J., He, B., Li, X., Yan, H., Liu, S., Yang, Y., Zhou, D., Liu, B., Fan, X., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109401 · Cited by 39 · see citing works

A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice

Bliss, C. M., Freyn, A. W., Caniels, T. G., Leyva-Grado, V. H., Nachbagauer, R., Sun, W., Tan, G. S., Gillespie, V., McMahon, M., Krammer, F., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.011 · Cited by 40 · see citing works

Leveraging deep learning to improve vaccine design

Hederman, A. P., & Ackerman, M. E. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.03.002 · Cited by 40 · see citing works

Targeting herpesvirus entry complex and fusogen glycoproteins with prophylactic and therapeutic agents

Zhong, L., Zhang, W., Krummenacher, C., Chen, Y., Zheng, Q., Zhao, Q., Zeng, M., Xia, N., Zeng, Y., Xu, M., et al. (2023) · Trends in Microbiology · doi:10.1016/j.tim.2023.03.001 · Cited by 38 · see citing works

Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice

van der Fits, L., Bolder, R., der Meer, M. H.-V., Drijver, J., van Polanen, Y., Serroyen, J., Langedijk, J. P. M., Schuitemaker, H., Saeland, E., & Zahn, R. C. (2020) · npj Vaccines · doi:10.1038/s41541-020-0200-y · Cited by 36 · see citing works

Potent cross-neutralization of respiratory syncytial virus and human metapneumovirus through a structurally conserved antibody recognition mode

Wen, X., Suryadevara, N., Kose, N., Liu, J., Zhan, X., Handal, L. S., Williamson, L. E., Trivette, A., Carnahan, R. H., Jardetzky, T. S., et al. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.07.002 · Cited by 36 · see citing works

Fatal enhanced respiratory syncytial virus disease in toddlers

Polack, F. P., Álvarez-Paggi, D., Libster, R., Caballero, M. T., Blair, R. V., Hijano, D. R., Niveyro, P. X. D. L. I., Menéndez, D., Gladwell, W., Avendano, L. M., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abj7843 · Cited by 37 · see citing works

Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases

Rouf, N. Z., Biswas, S., Tarannum, N., Oishee, L. M., & Muna, M. M. (2022) · RNA Biology · doi:10.1080/15476286.2022.2055923 · Cited by 36 · see citing works

Contribution of Dendritic Cells in Protective Immunity against Respiratory Syncytial Virus Infection

Jung, H. E., Kim, T. H., & Lee, H. K. (2020) · Viruses · doi:10.3390/v12010102 · Cited by 35 · see citing works

Optimization of a Plasmodium falciparum circumsporozoite protein repeat vaccine using the tobacco mosaic virus platform

Langowski, M. D., Khan, F. A., Bitzer, A. A., Genito, C. J., Schrader, A. J., Martin, M. L., Soto, K., Zou, X., Hadiwidjojo, S., Beck, Z., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1911792117 · Cited by 35 · see citing works

Crystal Structure and Immunogenicity of the DS-Cav1-Stabilized Fusion Glycoprotein From Respiratory Syncytial Virus Subtype B

Joyce, M. G., Bao, A., Chen, M., Georgiev, I. S., Ou, L., Bylund, T., Druz, A., Kong, W., Peng, D., Rundlet, E. J., et al. (2019) · Pathogens and Immunity · doi:10.20411/pai.v4i2.338 · Cited by 35 · see citing works

Safety, Tolerability, and Immunogenicity of an mRNA-Based Respiratory Syncytial Virus Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial

Shaw, C. A., Mithani, R., Kapoor, A., Dhar, R., Wilson, L., Asmar, L. E., Ghamloush, S. S., Schaefers, K., August, A., Stoszek, S., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae035 · Cited by 35 · see citing works

Landscape of respiratory syncytial virus

Duan, Y., Liu, Z., Zang, N., Cong, B., Shi, Y., Xu, L., Jiang, M., Wang, P., Zou, J., Zhang, H., et al. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003354 · Cited by 36 · see citing works

The respiratory syncytial virus (RSV) prefusion F‐protein functional antibody repertoire in adult healthy donors

Andreano, E., Paciello, I., Bardelli, M., Tavarini, S., Sammicheli, C., Frigimelica, E., Guidotti, S., Torricelli, G., Biancucci, M., D’Oro, U., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114035 · Cited by 34 · see citing works

COVID‐19 vaccines: Knowing the unknown

Lv, H., Wu, N. C., & Mok, C. K. P. (2020) · European Journal of Immunology · doi:10.1002/eji.202048663 · Cited by 32 · see citing works

Vaccines against human respiratory syncytial virus in clinical trials, where are we now?

Rossey, I., & Saelens, X. (2019) · Expert Review of Vaccines · doi:10.1080/14760584.2019.1675520 · Cited by 32 · see citing works

Building a better RSV vaccine

Scanlon, S. T. (2019) · Science · doi:10.1126/science.365.6452.458-p

Novel antigens for RSV vaccines

Graham, B. S., Modjarrad, K., & McLellan, J. S. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.04.005 · Cited by 151 · see citing works

Structure-Based Vaccine Antigen Design

Graham, B. S., Gilman, M. S. A., & McLellan, J. S. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-121217-094234 · Cited by 234 · see citing works

Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein

McLellan, J. S. (2015) · Current Opinion in Virology · doi:10.1016/j.coviro.2015.03.002 · Cited by 139 · see citing works

Structure-based Vaccine Design: Lessons from RSV F

McLellan, J. S. (2016)